Visilizumab

Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells.

It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease. PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.

Nevertheless, clinical trials continue for various diseases like multiple myeloma and diabetes mellitus type 1 . Visilizumab has also been radiolabelled with technetium-99m for imaging T cells.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1184154654 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.